Sun Pharma announces divestment of US manufacturing unit
Divests Bryan unit to Nostrum Laboratories
Mumbai, December 14, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma) today announced that as a part of its manufacturing consolidation in the US, one of its wholly owned subsidiaries has entered into an agreement with Nostrum Laboratories Inc. (Nostrum) for the divestment of the Bryan (Ohio) unit in the US.
As a part of the agreement, the Sun Pharma subsidiary has divested this unit as a going concern along with the employees and related products to Nostrum. During the divestment process, Sun Pharma was cognizant that the interests of its employees working in the unit were not compromised.
While other details of the transaction are confidential, the financial impact of this development on Sun Pharma is negligible.
About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 49 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2015 are approximately US$ 4.5 billion, of which US contributes US$ 2.2 billion. In India, the company enjoys leadership across 13 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues. For further information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live
You have received this email as your address is part of our Investor Relations and Media Contacts list. All our Press Releases and Financial updates are sent to those on the list.
• If you wish to be removed from this list or your address has been accidentally included here, then please let us know by a return email and we will remove it.
All the others will continue to be on the mailing list.
• If you wish to receive emails on some other email id, please send it to us.
• If you think that somebody else from your organisation should be added to this list, then please ask him / her to send us an email and we will add.
• If you are changing jobs, please send us your new email id. We would like to be in touch with you and keep you updated on happenings at Sun Pharma.
We would be happy to host one-on-one, group and telephone meetings for updates on the Company. If you wish to setup such a meeting, feel free to get in touch with us. In-person meetings can be at our office or elsewhere depending on mutual convenience. Our contact details: